Overview

Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19

Status:
Active, not recruiting
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
Phase:
Phase 3
Details
Lead Sponsor:
R-Pharm
Treatments:
Favipiravir